Antineoplastic agent workplace contamination study: The Alberta Cancer Board Pharmacy perspective Phase III

Journal of Oncology Pharmacy Practice

Volumn 15, Issue 3, 2009, Pages 157-160

  Bigelow, Susan ^a   Schulz, Heidi ^b   Dobish, Roxanne ^b   Chambers, Carole R ^c  

^a TOM BAKER CANCER CENTRE   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

^c Alberta Cancer Board   (Canada)

Author keywords

Cyclophosphamide; Cytotoxic agent; Routine monitoring; Tertiary site; Workplace contamination

Indexed keywords

CYCLOPHOSPHAMIDE; SODIUM HYDROXIDE;

ARTICLE; CANADA; CLINICAL TRIAL; DRUG CONTAMINATION; DRUG MONITORING; ENVIRONMENTAL MONITORING; FEASIBILITY STUDY; GAS CHROMATOGRAPHY; HUMAN; MEDICAL PRACTICE; OCCUPATIONAL HAZARD; PHARMACY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TERTIARY HEALTH CARE; WORKPLACE;

ALBERTA; ANTINEOPLASTIC AGENTS; CYCLOPHOSPHAMIDE; ENVIRONMENTAL MONITORING; ENVIRONMENTAL POLLUTION; GLOVES, PROTECTIVE; OCCUPATIONAL EXPOSURE; PHARMACY SERVICE, HOSPITAL;

EID: 69849107947     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155208101097     Document Type: Article

References (4)

1. Schulz H., Bigelow S., Dobish R., Chambers CR Antineoplastic agent workplace contamination study: The Alberta Cancer Board Pharmacy perspective. Journal of Oncology Pharmacy Practice. 2005; 11(3): 101-109.
2. American Society of Hospital Pharmacissts. ASHP technical assistance bulletin on handling cytotixic drugs in hospitals. AM J Hosp Pharm 1990; 47: 1033-49.
3. Exposure Control, PO Box 467, 6600. Instructions of Use, Cyto Wipe Kit, AL Wijchen, the Netherlands. Retrieved from http://www.exposurecontrol.nl (accessed 27 February 2003).
4. Connor TH, Anderson RW, Sessink PJ, Broadfield L., Power LA et al. Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Am J Health-Syst Pharm. 1999; 56: 1427-32.